PartnershipMay 5, 2026, 06:02 AM
Aclarion expands Weill Cornell partnership with new Nociscan trial
AI Summary
Aclarion, Inc. announced a second commercial agreement with Weill Cornell Medicine, integrating its Nociscan platform into a new 2-year prospective randomized controlled trial. Led by neurosurgeon Dr. Roger Härtl, the study will evaluate lumbar microdiscectomy surgery outcomes and disc degeneration, aiming to advance understanding of chronic low back pain. Nociscan, a healthcare technology leveraging AI and biomarkers, helps physicians identify painful discs and has demonstrated a 97% surgical success rate. This partnership expands Nociscan's presence and validates its innovative approach.
Key Highlights
- Aclarion established a second commercial agreement with Weill Cornell Medicine.
- Nociscan platform will be used in a new 2-year prospective randomized controlled trial.
- The trial, led by Dr. Roger Härtl, focuses on degenerative disc disease.
- Nociscan helps identify painful discs with a 97% surgical success rate.
- Chronic low back pain affects approximately 266 million people worldwide.